Overactive
1 clinical trials · Condition
| Record | Firm | Date |
|---|---|---|
| OnabotulinumtoxinA for the Treatment of Urinary Incontinence Due to Overactive Bladder in Pediatric Patients (12 to 17) (NCT02097121) | Allergan | 2014-05-23 |
Track Overactive automatically
Every clearance here is in the API, with alerts when new ones post.